{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000000", "text": "# ESGO_OvarianCancer_PocketGuidelines_2025", "section": "ESGO_OvarianCancer_PocketGuidelines_2025", "page_from": null, "page_to": null, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b99268e244656bbbbef00d657a5f345b9deee4f9643d7fa8e19b28b6efc47a1f"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000001", "text": "PUBLISHED IN 2024\nOVARIAN\nCANCER\nPOCKET\nGUIDELINES", "section": "PUBLISHED IN 2024", "page_from": 1, "page_to": 1, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3afe648d94fe7a9f15767be7977c2e7e96eee3f0433231f443357c35a2fe18f6"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000002", "text": "2", "section": "PUBLISHED IN 2024", "page_from": 2, "page_to": 2, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d4735e3a265e16eee03f59718b9b5d03019c07d8b6c51f90da3a666eec13ab35"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000003", "text": "3\nPOCKET GUIDELINES\nBased on\nESGO-ESMO-ESP consensus conference\nrecommendations on ovarian cancer:\npathology and molecular biology and early,\nadvanced and recurrent disease\nLedermann, J. Matias-Guiu, X., … Fagotti, A. (2024). ESGO-ESMO-ESP consensus\nconference recommendations on ovarian cancer: pathology and molecular biology and,\nearly, advanced and recurrent disease. Annals of Oncology. Mar;35(3):248-266.\ndoi: 10.1016/j.annonc.2023.11.015", "section": "POCKET GUIDELINES", "page_from": 3, "page_to": 3, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "596fe81e39385ff501dfe2913191bf2649f8311cd2073fc93de03459def78cc0"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000004", "text": "4\nThe development of guidelines is one of the core activities of both the European\nSociety of Gynaecological Oncology (ESGO) and the European Society for Medical\nOncology (ESMO), as part of their mission to improve the quality of care for pati-\nents with cancer across Europe. The European Society of Pathology (ESP) promotes\nhigh-quality pathology diagnosis for all patients. Following the 2018 ESMO-ESGO\nconsensus conference (CC) on ovarian cancer, another CC took place on 15-16\nJune 2022 in Valencia, Spain. Pathology expertise was added by including ESP. Fo-\nllowing the ESMO Standard Operating Procedures (SOPs) for CC, the aim was to\ndiscuss new or contentious topics and develop recommendations to improve and\nharmonise the management of patients with ovarian cancer.\nThe need for a CC was identified by the ESGO and ESMO Guidelines Committees.\nA. Fagotti (ESGO), J. Ledermann (ESMO) and X. Matias-Guiu (ESP) were designated\nas CC Chairs. The CC Chairs defined four broad topics and assigned 41 additional\nexperts from Europe with representation from Asia and the United States of Ameri-\nca to four working groups (WGs) based on their expertise, ensuring good represen-", "section": "The development of guidelines is one of the core activities of both the European", "page_from": 4, "page_to": 4, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "003176927aeb8cb61e57f3ede81f9650e61c7cacbf19dd184609adf39a2c0f3b"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000005", "text": "experts from Europe with representation from Asia and the United States of Ameri-\nca to four working groups (WGs) based on their expertise, ensuring good represen-\ntation across the three societies. An ESMO scientific advisor and a methodologist\n(ESGO) were also included in the CC panel. Two WG Chairs for each WG were\nnominated by the CC Chairs as follows:\n1.\t Pathology and molecular biology (Chairs: B. Davidson and A. Leary);\n2.\t Early-stage disease and pelvic mass in pregnancy (Chairs: F. Amant and C. Gourley);\n3.\t Advanced stage (including older/frail patients) (Chairs: N. Concin and D. Lorusso);\n4.\t Recurrent disease (Chairs: C. Fotopoulou and A. González-Martín).\nLiterature search was conducted by the ESGO methodologist using the Medline®\ndatabase to ensure that the recommendations were evidence-based. Prior the CC,\nthe WGs discussed published data and clinical experience and drafted recommen-\ndations. Organisation of the pre-consensus process and onsite conference was ma-\nnaged by the ESMO Guidelines staff.\nDuring the CC, the four WGs further discussed and agreed on the draft recommen-\ndations in parallel sessions. These were presented to the entire panel before voting,", "section": "The development of guidelines is one of the core activities of both the European", "page_from": 4, "page_to": 4, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "47a830f1f0e8bbb32381054c75d2f4297fe4bfc7ed3f1b4723e4330f8b111efb"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000006", "text": "During the CC, the four WGs further discussed and agreed on the draft recommen-\ndations in parallel sessions. These were presented to the entire panel before voting,\nwhere they were discussed and modified as required. Forty individuals were eligible\nto vote on recommendations (3 CC Chairs, 8 WG Chairs and 29 WG members). Four\nWG members were unable to attend/vote in person but participated in post-CC vo-\nting. The ESGO methodologist and the ESMO scientific advisor did not participate in\nthe voting of recommendations. Voting was anonymous. Members could abstain from\nvoting if they perceived that they had insufficient expertise or a conflict of interest.", "section": "The development of guidelines is one of the core activities of both the European", "page_from": 4, "page_to": 4, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e4eed3543356df83a4d405f80b5c8fa8a50064ac1e96d9a77c52f7c8730a0e97"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000007", "text": "5\nI\nEvidence from at least one large randomised, controlled trial of good methodologi-\ncal quality (low potential for bias) or meta-analyses of well conducted, randomised\ntrials without heterogeneity\nII\t Small randomised trials or large randomised trials with a suspicion of bias (lower\nmethodological quality) or meta-analyses of such trials or of trials with demonstra-\nted heterogeneity\nIII\t Prospective cohort studies\nIV\t Retrospective cohort studies or case-control studies\nV\t Studies without control group, case reports, expert opinions\nLEVELS OF EVIDENCE\nA\t Strong evidence for efﬁcacy with a substantial clinical beneﬁt, strongly recommended\nB\t Strong or moderate evidence for efﬁcacy but with a limited clinical beneﬁt, gene-\nrally recommended\nC\t Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the risk or the dis-\nadvantages (adverse events, costs…), optional\nD\t Moderate evidence against efﬁcacy or for adverse outcome, generally not recom-\nmended\nE\t Strong evidence against efﬁcacy or for adverse outcome, never recommended\nGRADES OF RECOMMENDATIONS\nFor recommendations that did not reach consensus onsite after two rounds of voting,", "section": "I", "page_from": 5, "page_to": 5, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "824d238009ec0d5cfd2bd8c230a80675720ef60a64e40c588c44bb8368a03d38"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000008", "text": "mended\nE\t Strong evidence against efﬁcacy or for adverse outcome, never recommended\nGRADES OF RECOMMENDATIONS\nFor recommendations that did not reach consensus onsite after two rounds of voting,\na post-CC exploration of disagreements was conducted using a modified Grading\nof Recommendations, Assessment, Developmentand Evaluation (GRADE) methodo-\nlogy, described in the ESMO SOPs. The aim was to provide further insight into the\ndivision of opinions to illustrate the extent to which consensus was/was not likely.\nAn adapted version of the ‘Infectious Diseases Society of America-United States Pu-\nblic Health Service Grading System’ was used to define the level of evidence and\ngrade of recommendation for each recommendation proposed, based on the data\navailable up to the time of the CC:\nThese ESGO-ESMO-ESP CC recommendations are intended for use by all health pro-\nfessionals involved in the management of patients with ovarian cancer across all\nallied disciplines. They do not include any economic analysis of the strategies. Any\nclinician seeking to apply or consult these CC recommendations is expected to use", "section": "I", "page_from": 5, "page_to": 5, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e8bed6dc72b3b5081803511fa296505c8f53ec94484c161b420a8e8e22677a09"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000009", "text": "allied disciplines. They do not include any economic analysis of the strategies. Any\nclinician seeking to apply or consult these CC recommendations is expected to use\nindependent medical judgment in the context of individual clinical circumstances to\ndetermine any patient’s care or treatment.", "section": "I", "page_from": 5, "page_to": 5, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "42498caaa72d73a65d12bec2e4d6f435d41a5600fac9844dabeac17cd757bbbe"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000010", "text": "6\nNAME\nSPECIALTY\nAFFILIATION\nAnna Fagotti\nGynaecologic oncologist\nFondazione Policlinico Universitario A. Gemelli\n\n(CC chair)\n IRCCS, Rome (Italy), Child and Public Health, Catholic\n\nUniversity of Sacred Heart, Rome (Italy)\nJonathan Ledermann\nMedical oncologist (CC chair)\nUCL Cancer Institute, University College London,\n\nLondon (United Kingdom)\nXavier Matias-Guiu\nPathologist (CC chair)\nHospital Universitari Arnau de Vilanova, IRBLLEIDA,\n\nUniversity of Lleida, Lleida (Spain), Hospital Universitari de\n\nBellvitge, IDIBELL, University of Barcelona, Barcelona (Spain)\nFrançois Planchamp\nMethodologist\nInstitut Bergonié, Bordeaux, (France)\nFrédéric Amant\nGynaecologic oncologist\nKU Leuven, Leuven (Belgium), Antoni van Leeuwenhoek\n\nNederlands Kanker Instituut, Amsterdam\n\n(The Netherlands)\nSusana Banerjee\nMedical oncologist\nThe Royal Marsden NHS Foundation Trust and Institute\n\nof Cancer Research, London (United Kingdom)\nLuis Chiva\nGynaecologic oncologist\nCancer Center Clínica Universidad de Navarra,\n\nNavarra (Spain)\n\nDavid Cibula\nGynaecologic oncologist\nFirst Faculty of Medicine, Charles University and General\n\nUniversity Hospital in Prague, Prague (Czech Republic)\nNicoletta Colombo", "section": "NAME", "page_from": 6, "page_to": 6, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3075b214ae3f09b10d23a169b9f07c7c844b61f13c616b5244e4924b8664083d"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000011", "text": "Navarra (Spain)\n\nDavid Cibula\nGynaecologic oncologist\nFirst Faculty of Medicine, Charles University and General\n\nUniversity Hospital in Prague, Prague (Czech Republic)\nNicoletta Colombo\nObstetrician & gynaecologist\nIstituto Europeo di Oncologia IRCCS, Milan (Italy)\n\nUniversity of Milano-Bicocca, Milan (Italy)\nNicole Concin\nGynaecologic oncologist\nMedical University of Innsbruck, Innsbruck (Austria)\nSabrina Croce\nPathologist\nInstitut Bergonié, Bordeaux (France)\nBen Davidson\nPathologist\nThe Norwegian Radium Hospital, Oslo University\n\nHospital, Oslo (Norway)\n\nInstitute of Clinical Medicine, Faculty of Medicine,\n\nUniversity of Oslo, Oslo, (Norway)\n\nClaire Falandry\nMedical oncologist\nInstitute of Aging, Hospices Civils de Lyon, Lyon (France),\n\nCarMeN Laboratory, INSERM U1060/Université Lyon 1/\n\nINRAE U1397/Hospices Civils Lyon, Pierre-Bénite (France)\nDaniela Fischerová\nGynaecologic oncologist\nFirst Faculty of Medicine, Charles University and General\n\nUniversity Hospital in Prague, Prague (Czech Republic)\nChristina Fotopoulou\nGynaecologic oncologist\nFaculty of Medicine, Imperial College London,\n\nLondon (United Kingdom)\nAne Gerda Zahl Eriksson\nGynaecologic oncologist", "section": "NAME", "page_from": 6, "page_to": 6, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "bcfdfc2cd22c88321643f96ce3f312be8906aef3b23e6fb18d91cdbae57e8ec5"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000012", "text": "Christina Fotopoulou\nGynaecologic oncologist\nFaculty of Medicine, Imperial College London,\n\nLondon (United Kingdom)\nAne Gerda Zahl Eriksson\nGynaecologic oncologist\nThe Norwegian Radium Hospital, Oslo University\n\nHospital, Oslo (Norway), Institute of Clinical Medicine,\n\nFaculty of Medicine, University of Oslo, Oslo, (Norway)\nAntonio González-Martín\nMedical oncologist\nCancer Center Clínica Universidad de Navarra,\n\nMadrid (Spain)\n\nCharlie Gourley\nMedical oncologist\nCancer Research UK Scotland Centre, Institute\n\nof Genetics and Cancer, University of Edinburgh,\n\nEdinburgh (United Kingdom)\n\nPhilipp Harter\nGynaecologic oncologist\nEvang. Kliniken Essen-Mitte, Essen (Germany)\nFlorence Joly\nMedical oncologist\nCentre François-Baclesse, University of Caen\n\nNormandy, Caen (France)\nConxi Lazaro\nMolecular geneticist\nCatalan Institute of Oncology (ICO–IDIBELL–CIBERONC),\n\nL’Hospitalet de Llobregat, Barcelona (Spain)\nAlexandra Leary\nMedical oncologist\nInstitut Gustave Roussy, Villejuif (France)\nESGO would like to thank all the participants of the ESGO-ESMO-ESP CC for their constant\navailability, work, and for making possible the development of these CC recommendations\non ovarian cancer (see below).", "section": "NAME", "page_from": 6, "page_to": 6, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "72d91eb66b1cc7800a32953e3ee82e2745a8bede5fd8031cba7d9f57ba299d56"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000013", "text": "7\nDomenica Lorusso\nObstetrician & gynaecologist\nFondazione Policlinico Universitario A. Gemelli IRCCS,\n\nRome (Italy), Catholic University of Sacred Heart,\n\nRome (Italy)\nChristianne Lok\nGynaecologic oncologist\nCenter for Gynecological Oncology Amsterdam,\n\n Netherlands Cancer Institute, Amsterdam\n\n(The Netherlands)\n\nSven Mahner\nGynaecologic oncologist\nUniversity Hospital, LMU Munich, Munich (Germany)\nFrederik Marmé\nGynaecologic oncologist\nUniversity Hospital Mannheim, Mannheim (Germany)\n\nMedical Faculty Mannheim, Heidelberg University,\n\nMannheim (Germany)\n\nChristian Marth\nGynaecologic oncologist\nMedical University of Innsbruck, Innsbruck (Austria)\nGlenn McCluggage\nPathologist\nBelfast Health and Social Care Trust, Belfast (United Kingdom)\nIan McNeish\nMedical oncologist\nFaculty of Medicine, Imperial College London,\n\nLondon (United Kingdom)\nPhilippe Morice\nGynaecologic oncologist\nGustave Roussy Cancer Campus, Villejuif (France)\nShibani Nicum\nMedical oncologist\nUCL Cancer Institute, University College London,\n\nLondon (United Kingdom)\nAna Oaknin\nMedical oncologist\nVall d’Hebron Institute of Oncology (VHIO), Hospital\n\nUniversitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital", "section": "Domenica Lorusso", "page_from": 7, "page_to": 7, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "bdc3a60f89bb3e37cebf1ae05b607b54c091f03511e6930f6ed022add41b1c43"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000014", "text": "London (United Kingdom)\nAna Oaknin\nMedical oncologist\nVall d’Hebron Institute of Oncology (VHIO), Hospital\n\nUniversitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital\n\nCampus, Barcelona (Spain)\nJose Alejandro Pérez-Fidalgo\nMedical oncologist\nHospital Clínico Universitario – INCLIVA, CIBERONC,\n\nValencia (Spain)\n\nSandro Pignata\nMedical oncologist\nIstituto Nazionale Tumori di Napoli, IRCCS Fondazione\n\nPascale, Napoli (Italy)\n\nPedro Ramirez\nObstetrician & gynaecologist\nHouston Methodist Hospital, Houston\n\n(United States of America)\nIsabelle Ray-Coquard\nMedical oncologist\nCentre Léon Bérard, Lyon (France)\n\nIgnacio Romero\nMedical oncologist\nInstituto Valenciano Oncologia, Valencia (Spain)\nGiovanni Scambia\nEndoscopist, surgeon\nFondazione Policlinico Universitario A. Gemelli IRCCS,\n\nRome (Italy), Catholic University of Sacred Heart,\n\nRome (Italy)\nRonnie Shapira-Frommer\nMedical oncologist\nSheba Medical Center, Ramat Gan (Israel)\nJalid Sehouli\nGynaecologic oncologist\nCharité-Universitätsmedizin, Berlin (Germany)\nCristiana Sessa\nMedical oncologist\nOncology Institute of Southern Switzerland (IOSI),\n\n(scientific advisor)\n Bellinzona (Switzerland)\nSudha Sundar\nGynaecologic oncologist", "section": "Domenica Lorusso", "page_from": 7, "page_to": 7, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9834207eecb268c548e83452e2325d03db7f5beb403d9effe23fa92763c1b9c3"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000015", "text": "Cristiana Sessa\nMedical oncologist\nOncology Institute of Southern Switzerland (IOSI),\n\n(scientific advisor)\n Bellinzona (Switzerland)\nSudha Sundar\nGynaecologic oncologist\nInstitute of Cancer and Genomic Sciences, University\n\nof Birmingham, Birmingham (United Kingdom)\n\nPan Birmingham Gynaecological Cancer Centre,\n\nCity Hospital, Birmingham (United Kingdom)\nDavid Tan\nMedical oncologist\nYong Loo Lin School of Medicine, National University\n\nof Singapore (Singapore), National University of Singapore\n\n(NUS) Centre for Cancer Research, Yong Loo Lin School\n\nof Medicine, National University of Singapore (Singapore)\n\nCancer Science Institute, National University of Singapore\n\n(Singapore), National University Cancer Institute Singapore,\n\nNational University Hospital, Singapore (Singapore)\nCagatay Taskiran\nGynaecologic oncologist\nSchool of Medicine, Koç University, Istanbul (Turkey)\nWillemien Van Driel\nGynaecologic oncologist\nCenter for Gynecological Oncology Amsterdam,\n\nNetherlands Cancer Institute, Amsterdam (The Netherlands)\nIgnace Vergote\nGynaecologic oncologist\nLeuven Cancer Institute, University Hospitals Leuven,\n\nLeuven (Belgium)\nNAME\nSPECIALTY\nAFFILIATION", "section": "Domenica Lorusso", "page_from": 7, "page_to": 7, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e73218b625fe1bbaa453f0eef87097f5f2482755e2e9a98f2a7546e9507d8584"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000016", "text": "8\nTABLE OF CONTENTS\nPathology and molecular biology ...................................................................... 10\n1. \t Which molecular and genomic tests should be carried out\n\nat diagnosis as prognostic or predictive markers for high-grade\n\ntubo-ovarian carcinoma?.............................................................................. 10\n2. \t What is the role of circulating and tissue biomarkers during treatment\n\nand follow-up?............................................................................................. 10\n3. \t How should low-grade serous carcinoma (LGSC) and high-grade serous\n\ncarcinoma (HGSC) be diagnosed?................................................................. 11\n4. \t What is the role of molecular classification in ovarian endometrioid\n\ncarcinoma (EC) and clear-cell carcinoma (CCC)?............................................ 12\nEarly-stage disease and pelvic mass in pregnancy ........................................... 12\n5. \t How should an adnexal mass be managed in pregnant women?.................. 12\n6. \t How should an adnexal mass be managed for women who want to retain", "section": "TABLE OF CONTENTS", "page_from": 8, "page_to": 8, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "97a461c4a02e5a189f9d388e1fe98486a213865044266abb871d4e1813a11361"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000017", "text": "5. \t How should an adnexal mass be managed in pregnant women?.................. 12\n6. \t How should an adnexal mass be managed for women who want to retain\n\ntheir fertility?................................................................................................ 12\n7. \t How should high-grade EC, CCC and high-risk mucinous stage I-II\n\ntubo-ovarian carcinomas be managed?......................................................... 13\n8. \t How should ovarian serous borderline tumours with peritoneal implants\n\nbe managed?............................................................................................... 14\n9. \t How should early-stage LGSC with non-invasive peritoneal implants\n\nbe managed? .............................................................................................. 14\n10. \tHow should incidental serous tubal intraepithelial carcinoma (STIC)\n\nor microscopic HGSC be managed?.............................................................. 14\nAdvanced stage (including older/frail patients)................................................ 15\n11. \tHow should patients with advanced tubo-ovarian carcinoma", "section": "TABLE OF CONTENTS", "page_from": 8, "page_to": 8, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d4dccb217fef685d534425ac1d1d4be3d85f4fa5012290c65e4ac3556cc63450"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000018", "text": "Advanced stage (including older/frail patients)................................................ 15\n11. \tHow should patients with advanced tubo-ovarian carcinoma\n\nbe selected for primary cytoreductive surgery?.............................................. 15\n12. \tWhat is the role of hyperthermic intraperitoneal chemotherapy (HIPEC)\n\nin newly diagnosed tubo-ovarian carcinoma?................................................ 16", "section": "TABLE OF CONTENTS", "page_from": 8, "page_to": 8, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4da88a0ae493b8b4c1c99a8e1c12d845c3aac58cf0b5171aae222b537059067c"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000019", "text": "9\n13. \tWhich patients should receive bevacizumab, maintenance therapy\n\nwith PARPis or the combination of PARPis with bevacizumab\n\nand for how long?.......................................................................................  17\n14. \tHow should older/frail patients with tubo-ovarian carcinoma\n\nbe investigated and treated?......................................................................... 18\nRecurrent disease ................................................................................................ 19\n15. \tWhat is the role of surgery in recurrent tubo-ovarian carcinoma?.................. 19\n16. \tWhat is the role of molecularly targeted therapy in recurrent disease?.......... 20\n17. \tWhat is the role of non-platinum drugs and supportive care options?........... 21\n18. \tWhat is recommended regarding evaluation of QoL/survivorship issues\n\nand follow-up after treatment?....................................................................  21", "section": "TABLE OF CONTENTS", "page_from": 9, "page_to": 9, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fcf7043764a976860ba5c1234499e092c7c8bd7a81bb67b6aad6c2f60a8685aa"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000020", "text": "10\n1. \tWhich molecular and genomic tests should be carried out\n\nat diagnosis as prognostic or predictive markers for high-grade\n     tubo-ovarian carcinoma?\nPathology and molecular biology\nAn adequate surgical specimen or image-guided biopsy of treatment-naive\ntumour is the preferred sample for diagnosis and molecular testing.\nIn all cases, the sample should contain a sufficient number of tumour cells\n(preferably ≥30%). A cell block from peritoneal or pleural effusions may be\nused for molecular analysis.\nBRCA-mut (germline and/or somatic) testing is recommended at diagnosis\nfor patients with high-grade non-mucinous tubo-ovarian carcinoma regard-\nless of stage.\nRoutine tumour testing for non-BRCA homologous recombination gene\nmutations is not required; however, it should be encouraged in the research\nsetting.\nGenomic instability tests are recommended in patients with BRCA wild-type\n(wt) high-grade non-mucinous International Federation of Gynecology and\nObstetrics stage III-IV tubo-ovarian carcinoma at diagnosis as this provides\nuseful predictive information for first-line maintenance therapy decisions.\nA genomic instability test that has been clinically validated in large cohorts", "section": "TABLE OF CONTENTS", "page_from": 10, "page_to": 10, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "cca88517dc6df512b953e853e2e39a0ff470734dcfef17b55c0a7f5b276ae6aa"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000021", "text": "useful predictive information for first-line maintenance therapy decisions.\nA genomic instability test that has been clinically validated in large cohorts\nor, preferably, phase III trials should be used.\nThere are no validated predictive markers of primary resistance to platinum\nor poly (ADP-ribose) polymerase inhibitors (PARPis) at diagnosis and none\ncan be recommended at present.\nGeneral population screening for tubo-ovarian carcinoma cannot be recom-\nmended because screening does not reduce cancer deaths.\nCA-125 with or without HE4 should not be used alone to differentiate bet-\nween benign, borderline and malignant ovarian tumours.\nA\nB\n2.\t What is the role of circulating and tissue biomarkers during\n\ntreatment and follow-up?\nRoutine monitoring of CA-125 after completion of first-line chemotherapy\nis an option that should be discussed with the patient.\nThe CA-125 ELIMination rate constant K calculated using longitudinal CA-\n125 over the first 100 days of treatment provides prognostic information,\nand testing for this dynamic circulating marker can be considered.\nA\nB\nA\nE\nD\nA\nA\nB\nB\nA", "section": "TABLE OF CONTENTS", "page_from": 10, "page_to": 10, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b1ef455120996c8349ee69b527ec3ba10d12651980715c7bcf2fdd376a361af7"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000022", "text": "11\nRoutine monitoring for circulating tumour DNA (ctDNA) and circulating\ntumour cells is not recommended but should be encouraged within the\ncontext of research projects.\nTesting ctDNA for reversion mutations can be considered in patients with\nBRCA-mutated tubo-ovarian carcinoma treated with at least one line of\nplatinum and eligible for PARPi treatment.\nChemotherapy response score at interval cytoreductive surgery on an\nomental (preferred) or adnexal specimen provides prognostic information\nand is recommended.\nTesting for a reversion mutation in tumour samples at relapse can be consi-\ndered in BRCA-mutated tumours.\nA\nC\n3.\t How should low-grade serous carcinoma (LGSC) and high-grade\n\nserous carcinoma (HGSC) be diagnosed?\nLGSC and HGSC should be regarded as two distinct neoplasms with diffe-\nrent morphology, underlying molecular events and behaviour and do not\nrepresent different grades of the same tumour type.\nThe distinction between LGSC and HGSC is based on a combination of\nmorphology and p53 immunohistochemistry (IHC); in diagnostically chal-\nlenging cases, referral for a specialist opinion and/or molecular testing is\nrecommended.", "section": "Testing ctDNA for reversion mutations can be considered in patients with", "page_from": 11, "page_to": 11, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8cffdd9a7c6ea6b338cd8bbb7f44222018a15875524abb535e4160302765e7c8"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000023", "text": "morphology and p53 immunohistochemistry (IHC); in diagnostically chal-\nlenging cases, referral for a specialist opinion and/or molecular testing is\nrecommended.\nIn cases with morphology suggestive of LGSC but aberrant p53 protein\nexpression and/or TP53 mutation, it is recommended that the tumour be\nclassified as HGSC.\nIn designating the primary site of extrauterine HGSC, the recommendations\nof the International Collaboration on Cancer Reporting should be followed.\nStaining for Wilms tumour protein (WT-1) is recommended when the pri-\nmary origin of HGSC (adnexal versus uterine) is unclear.\nResults of p53 IHC should be reported as ‘wt or normal’ or ‘mutation-type\nor aberrant’ rather than positive or negative.\nAs a minimum, paired box 8, oestrogen receptor, WT-1 and p53 IHC should\nbe carried out on diagnostic biopsies with a morphological suspicion of\nLGSC or HGSC.\nTesting for HER2 status in mucinous carcinoma can be considered to identi-\nfy patients who may benefit from HER2-targeted strategies.\nTesting for KRAS and BRAF mutational status in LGSC can be considered to\nidentify patients who may benefit from targeted strategies.\nB\nC\nA\nA\nA\nA\nA\nA\nA\nC\nC", "section": "Testing ctDNA for reversion mutations can be considered in patients with", "page_from": 11, "page_to": 11, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "53448265d564e686feb224eff1c8df968ca15dbeee4583a8dac325c3ec7eadae"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000024", "text": "12\n4.\t What is the role of molecular classification in ovarian endometrioid\n\ncarcinoma (EC) and clear-cell carcinoma (CCC)?\nA TCGA-based molecular classification as used for endometrial carcinomas\ncan be considered to stratify ovarian EC.\nMolecular markers are not recommended for prognostication in ovarian\nCCC.\nDNA mismatch repair IHC and/or microsatellite instability testing is recom-\nmended in ovarian EC and CCC.\n5.\t How should an adnexal mass be managed in pregnant women?\nEarly-stage disease and pelvic mass in pregnancy\nIt is recommended to evaluate all patients with suspicious adnexal masses\nduring pregnancy at a specialist referral centre.\nUltrasound by an expert is the recommended first-line imaging procedure\nwhen an adnexal mass is diagnosed during pregnancy.\nMagnetic resonance imaging (MRI) is recommended as a second stage test\nfor the characterisation of indeterminate ovarian masses.\nThe routine use of beta-human chorionic gonadotropin and alpha-fetopro-\ntein is not recommended during pregnancy.\nA proactive surgical approach depending upon gestational age is reco-\nmmended in cases of high risk for malignancy during pregnancy.", "section": "A TCGA-based molecular classification as used for endometrial carcinomas", "page_from": 12, "page_to": 12, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "478469cb7a76baa8fe6f6d81d7c047e538bb1b667ed26815bd1986b426f0cdf2"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000025", "text": "tein is not recommended during pregnancy.\nA proactive surgical approach depending upon gestational age is reco-\nmmended in cases of high risk for malignancy during pregnancy.\nWhere needed, platinum-based chemotherapy at the same dosage as in\nnon-pregnant women is recommended as standard chemotherapy after the\nfirst trimester of pregnancy.\nPaclitaxel can also be administered to pregnant women.\nPregnant patients who receive chemotherapy for ovarian carcinoma need\nfollow-up in high-risk obstetric units.\n6.\t How should an adnexal mass be managed for women who want to\n\nretain their fertility?\nThe option of fertility-sparing surgery should be discussed in young patients\nwith early-stage ovarian carcinoma.\nB\nD\nA\nA\nA\nA\nA\nA\nE\nA\nB\nA", "section": "A TCGA-based molecular classification as used for endometrial carcinomas", "page_from": 12, "page_to": 12, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "31e54cf66d7133858e000414feebdb3fc72f6bcd7ba15948d2139c3ccaa89422"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000026", "text": "13\nWomen with ovarian carcinoma who want to preserve their fertility need to\nbe managed in an oncofertility clinic.\nSubjective assessment of the adnexal mass by an ultrasound expert is recom-\nmended. If not available, the IOTA Assessment of Different NEoplasias in\nthe adneXa model (ADNEX) in combination with CA-125 is recommended\nto differentiate between benign, borderline, early- or advanced-stage ova-\nrian carcinoma and secondary carcinomas in young women who want to\npreserve their fertility.\nUnilateral salpingo-oophorectomy with surgical staging is recommended\nin young patients with a malignancy apparently confined to the ovary and\nwho want to preserve their fertility.\nMinimally invasive surgery avoiding tumour rupture is an acceptable approach\nfor women who wish to preserve their fertility.\nIt is not recommended to biopsy the unaffected ovary unless there is suspi-\ncion of involvement.\nIn patients who wish to retain their fertility, cryopreservation of gametes\nrather than ovarian tissue is recommended.\n7.\t How should high-grade EC, CCC and high-risk mucinous stage I-II\n\ntubo-ovarian carcinomas be managed?", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 13, "page_to": 13, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e5644bbb7498e5bac07e81420b84442810fbac156d442c81231b8d063c7ec834"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000027", "text": "rather than ovarian tissue is recommended.\n7.\t How should high-grade EC, CCC and high-risk mucinous stage I-II\n\ntubo-ovarian carcinomas be managed?\nComplete surgical resection including total abdominal hysterectomy, bilate-\nral-salpingo oophorectomy, omentectomy, systematic pelvic and para-aortic\nlymph node dissection, peritoneal biopsies and cytological analysis should\nbe the standard surgical procedure in stage I-II high-grade EC, CCC and\nhigh-risk mucinous ovarian carcinoma.\nPatients with stage I-II high-grade EC should be offered adjuvant platinum-\n-based chemotherapy.\nAdjuvant chemotherapy may be omitted for adequately staged IA or IB\nCCC.\nAdjuvant chemotherapy may be considered for stage IC1 CCC.\nAdjuvant chemotherapy is recommended for stages IC2, IC3 and II CCC.\nPatients with high-risk stage I-II mucinous ovarian carcinoma should be\noffered adjuvant platinum-based chemotherapy.\nA\nE\nA\nA\nC\nA\nA\nC\nA\nA\nA\nA", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 13, "page_to": 13, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "40eb6bac4d383e67b35fbe5494236125ee6955fc125385fa794282e2c8eadd61"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000028", "text": "14\n8.\t How should ovarian serous borderline tumours with peritoneal\n\nimplants be managed?\nSince the pathological analysis of implants is complex, it is recommended\nthat the histological review of specimens is carried out by an expert patho-\nlogist.\nIt is recommended to manage women with stage II-III ovarian serous bor-\nderline tumours at a specialist centre.\nIt is recommended to keep the distinction between invasive and non-inva-\nsive implants for subsequent management.\nIt is recommended to surgically resect peritoneal and omental disease to\ndifferentiate invasive from non-invasive implants.\n9.\t How should early-stage LGSC with non-invasive peritoneal implants\n\nbe managed?\nIt is recommended to completely remove all peritoneal implants combined\nwith peritoneal staging as a standard treatment procedure.\nRemoval of enlarged or suspicious lymph nodes is recommended without\nroutine systematic lymphadenectomy.\nAdjuvant chemotherapy could be considered for stage II LGSC.\nEndocrine treatment following chemotherapy could be considered for\nstage II LGSC.\n10.\t How should incidental serous tubal intraepithelial carcinoma\n\n (STIC) or microscopic HGSC be managed?", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 14, "page_to": 14, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d6db5ef308d93ce6776e8040d0106b124a42fcb1c79f18f439e07127181b760a"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000029", "text": "Endocrine treatment following chemotherapy could be considered for\nstage II LGSC.\n10.\t How should incidental serous tubal intraepithelial carcinoma\n\n (STIC) or microscopic HGSC be managed?\nIt is recommended that microscopic HGSC be managed as HGSC.\nSectioning and Extensively Examining the FIMbriated end (SEE-FIM) is recom-\nmended in risk-reducing bilateral salpingo-oophorectomy.\nSEE-FIM is recommended when there is doubt regarding the origin of the\ncarcinoma (endometrial, tubal, ovarian, peritoneal).\nIt is suggested that the pathologist examines microscopically the whole fim-\nbriae in benign conditions.\nIn STIC, staging of the peritoneum is recommended.\nA\nA\nA\nC\nA\nA\nA\nC\nA\nB\nA\nB\nA", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 14, "page_to": 14, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "41ab0c7cc9283b6f23ecc68dfb6c2f362d72544aa456f4f3ac475bbc613b06f8"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000030", "text": "15\nIn STIC, it is recommended that (re)-staging is carried out, preferably by\na minimally invasive procedure.\nIn STIC, hysterectomy should be considered, particularly in patients with\na germline BRCA1 mutation (gBRCA1-mut).\nIn STIC, if the uterus is preserved, endometrial sampling in patients with\na gBRCA1-mut is recommended.\nIn STIC, lymphadenectomy is not recommended.\nAdjuvant chemotherapy is not recommended in surgically staged STIC.\nIn cases of STIC, testing for gBRCA1/2-muts and other high-penetrance\nhereditary genes is mandatory.\n11.\t How should patients with advanced tubo-ovarian carcinoma\n\nbe selected for primary cytoreductive surgery?\nAdvanced stage (including older/frail patients)\nThe selection of patients for primary cytoreductive surgery or neoadjuvant\nchemotherapy (NACT) must be carried out in an accredited ovarian cancer\ncentre (according to the ESGO quality indicators for ovarian cancer surgery\n2016/2020) in a multidisciplinary setting.\nPrimary cytoreductive surgery is the preferred option and should be offered\nif a complete resection seems achievable.\nPrimary cytoreductive surgery is the preferred option in patients with LGSC", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 15, "page_to": 15, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "69f43bca985ff3468218ab3f84280dc2f256c6878d652dab80be30b319378921"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000031", "text": "Primary cytoreductive surgery is the preferred option and should be offered\nif a complete resection seems achievable.\nPrimary cytoreductive surgery is the preferred option in patients with LGSC\nif residual disease <1 cm can be achieved.\nNACT with interval cytoreductive surgery is a valid alternative for patients\nwith a low likelihood of initial complete resection and with chemosensitive\nhistological types or for those who are poor surgical candidates due to\nmedical conditions.\nPatients should be medically assessed for surgery, and this should be based\non clearly defined criteria requiring a thorough evaluation by a specialist\nin gynaecological oncology. Medically unfit patients should additionally re-\nceive an internal medicine and/or anaesthesiology evaluation. Eastern\nCooperative Oncology Group and American Society of Anesthesiology\nscores must be documented.\nCandidates for surgery based on a multidisciplinary team (MDT) report\nshould proceed to a laparotomy with the intent of complete cytoreduction.\nB\nA\nB\nE\nD\nA\nB\nA\nB\nA\nA\nA", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 15, "page_to": 15, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2b4f9f64436e2c7b90123ea57caceb92fbf44291591b81210b55d15252044f96"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000032", "text": "16\nContrast-enhanced computed tomography, MRI and positron emission\ntomography-computed tomography with a structured radiology report are\nconsidered as options for the initial evaluation of patients with advanced\novarian carcinoma.\nUltrasound by an expert sonographer may be used to assess tumour extent\nand resectability in the pelvis and abdominal cavity\nPatients must be counselled for cytoreductive surgery by providing an\nextensive discussion about the risk and benefits of the procedure specifi-\ncally for that patient and outlining a comprehensive list of potential peri-\noperative major and minor complications.\nPatients for whom there is concern for incomplete cytoreductive surgery\nbased on a structured radiology report may undergo a laparoscopic evalua-\ntion by a gynaecological oncologist to assess the extent of intra-abdominal\ndisease.\nScoring systems may play a role in guiding the evaluation and ultimately\ntriage patients for primary management. There is currently no universally\naccepted scoring system that could be recommended.\nCurrently, there are no specific validated biomarkers that are predictive of\nthe success of surgical resection.", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 16, "page_to": 16, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ec788cad2669e41e027f29547cc565e5314eb7602372072037532d7e57239412"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000033", "text": "accepted scoring system that could be recommended.\nCurrently, there are no specific validated biomarkers that are predictive of\nthe success of surgical resection.\nSystematic pelvic and para-aortic lymphadenectomy should not be carried\nout in patients with advanced disease who have undergone intra-abdo-\nminal macroscopically complete resection and have non-suspicious lymph\nnodes both on preoperative imaging and intraoperative clinical evaluation.\nEnlarged or suspicious lymph nodes should be removed to achieve comple-\nte resection.\nThe impact of resection of suspicious or enlarged extra-abdominal lymph\nnodes remains unclear but should be considered if complete macroscopic\nresection can be achieved intra-abdominally.\nResection of isolated parenchymal liver metastases should be considered to\nachieve a complete cytoreduction.\n12.\t What is the role of hyperthermic intraperitoneal chemotherapy\n\n(HIPEC) in newly diagnosed tubo-ovarian carcinoma?\nNo consensus on the role of HIPEC and interval cytoreductive surgery was reached, which\nreflects the current difference in opinion among the participants.\nC\nC\nA\nC\nA\nB\nE\nC\nA\nB", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 16, "page_to": 16, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9f9df8253f27c33397e8e81c9f417096e56c6920aab875fe44bd964dfc994e1b"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000034", "text": "17\n13.\t Which patients should receive bevacizumab, maintenance therapy\n\nwith PARPis or the combination of PARPis with bevacizumab\n\nand for how long?\nMolecular characteristics of tumour, patients and disease-related factors\nshould be considered in the decision-making process for maintenance\noptions.\nThe use of bevacizumab in combination with chemotherapy and as main-\ntenance is recommended independently from any biomarker.\nBevacizumab should be administered in combination with platinum-pac-\nlitaxel chemotherapy and as maintenance for a maximum of 15 months.\nCarcinosarcoma should be treated as HGSC.\nLGSC should be treated with paclitaxel-carboplatin chemotherapy with or\nwithout bevacizumab.\nChemotherapy followed by maintenance with endocrine therapy is an\noption in stage III and IV tumours.\nPatients with HGSC/high-grade EC and BRCA-muts or genomic instability\nscore (GIS)-positive (with a validated test) in complete response (CR)/partial\nresponse (PR)/no evidence of disease (NED) after platinum-based chemo-\ntherapy with or without bevacizumab should receive PARPis with or without\nbevacizumab.\nPatients with HGSC/high-grade EC without a BRCA-mut and who are GIS-", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 17, "page_to": 17, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "146242bd567e12202184f216e002043d070b8be6ad91befce61bd29884021692"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000035", "text": "therapy with or without bevacizumab should receive PARPis with or without\nbevacizumab.\nPatients with HGSC/high-grade EC without a BRCA-mut and who are GIS-\n-negative (with a validated test) may receive platinum-based chemotherapy\nin combination with bevacizumab followed by bevacizumab maintenance\nor platinum-based chemotherapy followed by niraparib or rucaparib if in\nCR/PR/NED. No maintenance treatment might be an option.\nPatients with HGSC/high grade EC without a BRCA-mut and GIS unknown\ncould receive platinum-based chemotherapy in combination with bevacizu-\nmab followed by bevacizumab maintenance or platinum-based chemothe-\nrapy followed by niraparib or rucaparib if in CR/PR/NED.\nWhen used as maintenance in patients in CR/PR/NED to platinum-based\nchemotherapy, olaparib (alone or in combination with bevacizumab) and\nrucaparib are recommended for 2 years, and niraparib is recommended for\n3 years.\nA\nB\nA\nA\nA\nB\nB\nB\nA\nA\nC", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 17, "page_to": 17, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1823981dd5a6bc73b628d082c5f8716b6d0fda8c30de0efd5dc421a0891a7c76"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000036", "text": "18\n14.\t How should older/frail patients with tubo-ovarian carcinoma\n\nbe investigated and treated?\nPatients should not be excluded from diagnostic procedures, clinical trials\nand specific treatments for tubo-ovarian carcinoma based only on chrono-\nlogical age.\nVulnerability should be assessed in patients 70 years or any age with at\nleast two comorbidities, if possible, with the support of a geriatric specialist.\nThis assessment should focus on patient functions (activities of daily living/\ninstrumental activities of daily living), nutrition, psychological well-being,\ncomorbidities and concomitant medications and should not delay the start\nof therapy.\nWhenever possible, considering vulnerability, complexity of surgery and pa-\ntient motivation, primary complete surgery is recommended.\nNACT can be considered as an alternative in patients with vulnerability and\nextensive disease.\nThe surgery should be carried out in expert centres involving scheduled\nsurgery, prehabilitation, intensive post-operative management, enhanced\nrecovery and home care.\nThe standard chemotherapy regimen is paclitaxel-carboplatin every 3 weeks.", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 18, "page_to": 18, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5673a93531d91887e9f7f186cabf7d3a13312cbd9bdc524a379ae2090c0997e9"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000037", "text": "surgery, prehabilitation, intensive post-operative management, enhanced\nrecovery and home care.\nThe standard chemotherapy regimen is paclitaxel-carboplatin every 3 weeks.\nThe continuous weekly paclitaxel 60 mg/m²-carboplatin area under the cur-\nve (AUC) 2 schedule may provide better tolerability and quality of life (QoL)\nand can be considered as an alternative option.\nWhen indicated, PARPis and/or bevacizumab should be offered to older\npatients carefully monitoring toxicity and concomitant medications.\nA\nD\nA\nB\nB\nA\nA", "section": "Women with ovarian carcinoma who want to preserve their fertility need to", "page_from": 18, "page_to": 18, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "264b98e1d78cf048d3283e1598c27ca2f31753056d83612bd0b00cdb0e691e29"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000038", "text": "19\n15.\t What is the role of surgery in recurrent tubo-ovarian carcinoma?\nRecurrent disease\nPatients with tubo-ovarian carcinoma in first relapse >6 months since the\nend of first-line platinum-based chemotherapy should be assessed for se-\ncondary cytoreductive surgery in a gynaecological oncology centre expe-\nrienced in surgery for ovarian cancer.\nProspectively validated algorithms should be used as a guide to identify\noptimal candidates for secondary cytoreductive surgery with complete\ntumour resection.\nNACT before cytoreductive surgery at relapse cannot be recommended\noutside of clinical trials.\nHIPEC is not recommended in cytoreductive surgery for relapsed disease.\nCytoreductive surgery could be offered to patients with subsequent relapses\nin whom complete resection appears feasible.\nIn selected patients, palliative surgery to relieve mechanical obstruction may\nbe indicated after failure of conservative measures, either to remove the\ntumour obstructing the bowel or to carry out a diversion procedure such as\na stoma. These patients should be managed within an MDT.\nPalliative surgery should be offered only after careful consideration in pa-", "section": "Recurrent disease", "page_from": 19, "page_to": 19, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c457cd573f3479218b9fe16f011bb9911965f45d5901dc5e70da176d1558c1fa"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000039", "text": "a stoma. These patients should be managed within an MDT.\nPalliative surgery should be offered only after careful consideration in pa-\ntients with unfavourable conditions, such as rapidly progressing disease\nwithout further systemic options, gastric outlet/upper gastrointestinal ob-\nstruction and multilevel sites of obstruction.\nFor oligometastatic recurrence, several treatment modalities such as surge-\nry, infield radiotherapy and thermal ablation should be considered within\nan MDT.\nThe following factors should be considered to decide treatment modali-\nty for oligometastatic recurrence: site of recurrence, time to recurrence,\nnumber of lesions, treatment-related morbidity, patient performance sta-\ntus, type of maintenance treatments and patient preferences, regardless of\ntheir BRCA status.\nAfter local ablative/surgical tumour management, continuation of main-\ntenance treatment with the same regimen could be considered.\nC\nB\nB\nB\nB\nD\nD\nB\nA\nA\nA", "section": "Recurrent disease", "page_from": 19, "page_to": 19, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "adda8853c1421c33f31379a4a9f5150f00aa11b87746a8a8e15941222323a9a1"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000040", "text": "20\n16.\t What is the role of molecularly targeted therapy in recurrent disease?\nFor patients with BRCA-mutated tumours, eligible for platinum and no prior\nPARPis and no prior bevacizumab use, a platinum-based combination fo-\nllowed by PARPis is recommended after CR/PR/NED. Bevacizumab may still\nbe considered depending on patient’s symptoms and response to chemo-\ntherapy.\nFor patients with BRCA-wt or unknown tumours eligible for platinum and\nno prior PARPis and no prior bevacizumab, maintenance therapy is recom-\nmended with PARPis (after CR/PR/NED) or bevacizumab. Bevacizumab\nadded to chemotherapy followed by maintenance should be prioritised for\npatients in need of rapid symptom control.\nFor patients eligible for platinum and no prior PARPis but prior bevacizu-\nmab, platinum-based chemotherapy followed by PARPi maintenance is\npreferred as long as CR/PR/NED is achieved, regardless of their BRCA and\nHRD status.\nFor patients eligible for platinum and prior PARPis but no prior bevacizu-\nmab, a platinum-based combination with bevacizumab followed by main-\ntenance should be recommended. The preferred chemotherapy partner for", "section": "Recurrent disease", "page_from": 20, "page_to": 20, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0854bdfb4d01cd2f941680fa3a1cac8237465f616ccd2e0a3a9e943e66a84e21"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000041", "text": "mab, a platinum-based combination with bevacizumab followed by main-\ntenance should be recommended. The preferred chemotherapy partner for\nbevacizumab in the recurrent setting is carboplatin-pegylated liposomal\ndoxorubicin (PLD).\nFor patients eligible for platinum and prior use of bevacizumab and PARPis,\na platinum-based chemotherapy should still be recommended and rechal-\nlenge options of maintenance agents could be considered.\nMonitoring of safety should be carried out according to drug-specific recom-\nmendations, with special focus on late safety issues.\nRoutine oncological follow-up is recommended including imaging and/or\nCA-125 according to local practice and after discussion with the patient.\nIn the recurrent setting, the duration of PARPis as maintenance should be\nuntil progressive disease or unacceptable toxicity.\nBevacizumab rechallenge in combination with platinum should be conside-\nred in patients already pre-treated with bevacizumab in the first line.\nThe preferred chemotherapy partner for bevacizumab (rechallenge) in the\nrecurrent setting is carboplatin-PLD.\nPatients in response to platinum-based chemotherapy after prior PARPi", "section": "Recurrent disease", "page_from": 20, "page_to": 20, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3b7a117628fc6e7c6d5876178e190ac4e82226ef3bf79cd37fa9f435333f9950"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000042", "text": "The preferred chemotherapy partner for bevacizumab (rechallenge) in the\nrecurrent setting is carboplatin-PLD.\nPatients in response to platinum-based chemotherapy after prior PARPi\nmaintenance therapy may be considered for a PARPi-maintenance rechal-\nlenge given a duration of prior PARPi exposure of 18 months in the first\nline and 12 months in further lines or 12 months and 6 months for patients\nwith a BRCA-mut or BRCA-wt status, respectively.\nA\nA\nA\nC\nA\nA\nB\nB\nA\nA\nA\nB", "section": "Recurrent disease", "page_from": 20, "page_to": 20, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "149e6e8d1a9eb3d9e62f0006188c309475961eb62e167559deb58c7cce2f6330"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000043", "text": "21\n17.\t What is the role of non-platinum drugs and supportive care options?\nFor patients progressing on platinum-based therapy or after a short treat-\nment-free interval or for those who are intolerant of platinum and not\neligible for platinum rechallenge, various management options should be\nconsidered, ranging from non-platinum single-agent systemic therapy to\nsupportive care alone.\nPatients should be included in clinical trials, when possible, as there is\na significant need for improved treatment options in this setting.\nFor patients who have not received prior bevacizumab, the addition of this\nagent to weekly paclitaxel, PLD or topotecan should be considered. The\ncombination of weekly paclitaxel and bevacizumab is the preferred option\nbased on trial subset analysis.\nThe combination of trabectedin and PLD could be considered in those pati-\nents who are intolerant to platinum who have relapsed after 6 months from\nthe last platinum dose.\nPatients with LGSC relapse should be considered for treatment with trame-\ntinib after platinum failure or for endocrine therapy.\nSupportive care alone should be considered when expected benefit of che-\nmotherapy is limited.", "section": "For patients progressing on platinum-based therapy or after a short treat-", "page_from": 21, "page_to": 21, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1441e19eeb628270c23e00a7263e21c7785f7488825656671e5ac4178b231721"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000044", "text": "tinib after platinum failure or for endocrine therapy.\nSupportive care alone should be considered when expected benefit of che-\nmotherapy is limited.\nSystematic assessment of QoL and symptoms during treatment is recom-\nmended to start early supportive care and prevent or improve symptoms,\nQoL and survival.\n18.\t What is recommended regarding evaluation of QoL/survivorship\n\nissues and follow-up after treatment?\nQoL and symptom assessment via validated tools could be considered as\npart of the routine follow-up in all patients with ovarian carcinoma.\nLong-term follow-up is recommended for all patients with tubo-ovarian\ncarcinoma by a physician experienced in the treatment and follow-up of\npatients with gynaecological cancer.\nA\nA\nA\nC\nA\nA\nA\nC\nA", "section": "For patients progressing on platinum-based therapy or after a short treat-", "page_from": 21, "page_to": 21, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2573657424ec114f597a3c656cd2d678a6e9d93a11bf1a8530ca5fcecb608843"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000045", "text": "22\nNOTES", "section": "NOTES", "page_from": 22, "page_to": 22, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "6d4262cf0efdcd35c8ee2317f427bfe1bae2139eb6dfed80463932106d8d3bb4"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000046", "text": "23\nAccess full ESGO Guidelines: www.esgo.org/explore/guidelines\n© 2025 European Society of Gynaecological Oncology\nAll rights reserved. No part of this book can be reprinted, reproduced, transmitted or utilised in any\nform by any electronic, mechanical, or other means, now known or hereafter invented, including\nphotocopying, microfilming, and recording, or any information storage or retrieval system, without\nwritten permissions of ESGO. Reasonable efforts have been made to publish reliable data and\ninformation, but the authors and publisher cannot assume responsibility for the validity of all mate-\nrials or for the consequences of their use, and the ultimate responsibility rests with the prescribing\nphysician.", "section": "NOTES", "page_from": 23, "page_to": 23, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "217da16b2c0cad6ce4eef58c1264152894cafef7ad57dc61d9b0165abbfc2552"}
{"doc_id": "esgo_ovariancancer_pocketguidelines_2025__v00000000", "chunk_id": "000047", "text": "© 2025 European Society of Gynaecological Oncology. All rights reserved.\nEuropean Society of Gynaecological Oncology\nAvenue Emmanuel Mounier, 83/11\n1200 Brussels, Belgium\nEmail: adminoffice@esgomail.org\nwww.esgo.org", "section": "European Society of Gynaecological Oncology", "page_from": 24, "page_to": 24, "display_name": "ESGO_OvarianCancer_PocketGuidelines_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c5fa0de3d23f4cfc53b6f86ed36b0f2133e6d602b904672f6e0a3e0bbcb3dd17"}
